Le mésothéliome pleural malin

J. Margery; D. Planchard

doi:10.1007/s10269-014-2395-x

Le mésothéliome pleural malin

Translated title of the contribution: Malignant pleural mesothelioma

J. Margery, D. Planchard

Research output: Contribution to journal › Review article › peer-review

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology and on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab was tested in an randomized phase 3 trial, MAPS, until December 2013.

Translated title of the contribution	Malignant pleural mesothelioma
Original language	French
Pages (from-to)	245-249
Number of pages	5
Journal	Oncologie
Volume	16
Issue number	5
DOIs	https://doi.org/10.1007/s10269-014-2395-x
Publication status	Published - 1 Jan 2014
Externally published	Yes

Access to Document

10.1007/s10269-014-2395-x

Cite this

@article{b34e4f360bdf461e8c56062fff8bea2b,

title = "Le m{\'e}soth{\'e}liome pleural malin",

abstract = "Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology and on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab was tested in an randomized phase 3 trial, MAPS, until December 2013.",

keywords = "Asbestosis, Diagnosis, Mesothelioma, Pleura, Treatment",

author = "J. Margery and D. Planchard",

year = "2014",

month = jan,

day = "1",

doi = "10.1007/s10269-014-2395-x",

language = "Fran{\c c}ais",

volume = "16",

pages = "245--249",

journal = "Oncologie",

issn = "1292-3818",

number = "5",

}

TY - JOUR

T1 - Le mésothéliome pleural malin

AU - Margery, J.

AU - Planchard, D.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology and on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab was tested in an randomized phase 3 trial, MAPS, until December 2013.

AB - Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology and on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab was tested in an randomized phase 3 trial, MAPS, until December 2013.

KW - Asbestosis

KW - Diagnosis

KW - Mesothelioma

KW - Pleura

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84902546550&partnerID=8YFLogxK

U2 - 10.1007/s10269-014-2395-x

DO - 10.1007/s10269-014-2395-x

M3 - Article 'review'

AN - SCOPUS:84902546550

SN - 1292-3818

VL - 16

SP - 245

EP - 249

JO - Oncologie

JF - Oncologie

IS - 5

ER -

Le mésothéliome pleural malin

Abstract

Access to Document

Other files and links

Cite this